VLX-1005 is under clinical development by Veralox Therapeutics and currently in Phase II for Heparin-Induced Thrombocytopenia. According to GlobalData, Phase II drugs for Heparin-Induced Thrombocytopenia have an 86% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how VLX-1005’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

VLX-1005 overview

VLX-1005 is under development for the treatment of heparin-induced thrombocytopenia (HIT), and HIT with thrombosis (HITT) and Type 1 diabetes. The therapeutic candidate acts by targeting 12 lipoxygenase (12-LOX) enzyme. It is administered through intravenous route and oral route.

Veralox Therapeutics overview

Veralox Therapeutics develops small molecule therapeutics that treat the underlying pathologies of thrombosis and type 1 diabetes. The company is headquartered in Frederick, Maryland, the US

For a complete picture of VLX-1005’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 7 February 2024

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.